Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Fusion Antibodies (FAB) Share Price

Price 6.90p on 14-03-2025 at 05:12:16
Change 0.00p 0%
Buy 7.00p
Sell 6.80p
Buy / Sell FAB Shares
Last Trade: Buy 5.00 at 6.97p
Day's Volume: 0
Last Close: 6.90p
Open: 0.00p
ISIN: GB00BDQZGK16
Day's Range 0.00p - 0.00p
52wk Range: 2.90p - 10.50p
Market Capitalisation: £7m
VWAP: 0.00p
Shares in Issue: 96m

Fusion Antibodies (FAB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 5 6.97p Ordinary
16:29:54 - 13-Mar-25
Buy* 9 6.97p Ordinary
16:29:35 - 13-Mar-25
Unknown* 14,710 6.90p Ordinary
16:28:48 - 13-Mar-25
Unknown* 14,565 6.90p Ordinary
16:24:14 - 13-Mar-25
Buy* 6 6.97p Ordinary
16:20:42 - 13-Mar-25
Sell* 10,000 6.8148p Ordinary
16:11:11 - 13-Mar-25
Unknown* 14,000 6.90p Ordinary
16:09:01 - 13-Mar-25
Sell* 7,865 6.82p Ordinary
16:06:48 - 13-Mar-25
Buy* 5 6.97p Ordinary
16:04:07 - 13-Mar-25
Sell* 329 6.80p SI Trade
16:03:55 - 13-Mar-25
See more Fusion Antibodies trades

Fusion Antibodies (FAB) Share Price History

Time period:
to
Date Open High Low Close Volume
14th Mar 2025 (Fri) 6.90 6.90 6.90 6.90 0
13th Mar 2025 (Thu) 6.90 7.05 6.90 6.90 484,979
12th Mar 2025 (Wed) 7.30 7.30 6.90 6.90 1,234,041
11th Mar 2025 (Tue) 8.05 8.05 7.25 7.35 1,348,780
10th Mar 2025 (Mon) 8.05 8.05 7.80 8.05 365,337
7th Mar 2025 (Fri) 7.75 7.80 7.75 7.80 307,788
6th Mar 2025 (Thu) 7.50 7.75 7.35 7.75 1,002,077
5th Mar 2025 (Wed) 7.35 7.50 7.35 7.50 340,440
4th Mar 2025 (Tue) 7.35 7.60 7.35 7.35 1,027,715
3rd Mar 2025 (Mon) 7.75 7.75 7.35 7.35 1,413,606
28th Feb 2025 (Fri) 8.00 8.00 7.65 7.75 263,194
27th Feb 2025 (Thu) 8.10 8.25 8.00 8.00 1,037,938
26th Feb 2025 (Wed) 7.95 8.10 7.95 8.10 410,629
25th Feb 2025 (Tue) 8.00 8.00 8.00 8.00 783,448
24th Feb 2025 (Mon) 8.05 8.05 8.00 8.00 338,590
21st Feb 2025 (Fri) 8.20 8.20 8.05 8.05 410,455
20th Feb 2025 (Thu) 8.10 8.25 8.00 8.20 508,399
19th Feb 2025 (Wed) 8.25 8.25 8.25 8.25 299,337
18th Feb 2025 (Tue) 7.35 8.35 7.35 8.25 2,003,874
17th Feb 2025 (Mon) 7.55 7.55 7.25 7.35 615,359
14th Feb 2025 (Fri) 7.75 7.75 7.35 7.55 1,159,754
See more Fusion Antibodies price history

Fusion Antibodies (FAB) Regulatory News

Date Source Headline
27th Feb 2025 7:00 am RNS Contract win
31st Jan 2025 7:00 am RNS OptiMAL R&D Update
4th Dec 2024 11:31 am RNS Approval of Grant Funding Application
19th Nov 2024 7:00 am RNS Half-year Report
16th Oct 2024 1:23 pm RNS Director/PDMR Shareholding
16th Oct 2024 7:00 am RNS Issue of shares to non-executive directors
8th Oct 2024 12:32 pm RNS Result of AGM
8th Oct 2024 7:00 am RNS AGM statement and trading update
2nd Oct 2024 7:00 am RNS Block admission six monthly return
12th Sep 2024 9:54 am RNS Notice of AGM
See more Fusion Antibodies regulatory news

Fusion Antibodies (FAB) Share News

Fusion Antibodies receives approval of grant funding application

4th Dec 2024 12:18

(Alliance News) - Fusion Antibodies PLC on Wednesday announced the approval of a grant funding application to The Northern Ireland Precision Biomarkers & Therapeutics consortium, of which it is a member. Read More

Fusion Antibodies interim loss narrows as revenue more than doubles

19th Nov 2024 13:10

(Alliance News) - Fusion Antibodies PLC on Tuesday said its loss narrowed in the first half of its current financial year, as revenue more than doubled. Read More

IN BRIEF: Fusion Antibodies expects interim revenue to double

8th Oct 2024 13:58

Fusion Antibodies PLC - Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Expects revenue of around GBP1.2 million for the six months to September 30, more than doubling from GBP541,000 at the same time last year. Its gross margin is expected to be 29%, compared to negative 16% the year prior. Fusion Antibodies expands its collaboration agreement with the National Cancer Institute in the six-month period to include the company's humanisation of the NCI's existing camelid nanobodies, and secures a new contract for an antibody based therapeutic with an unnamed US-based biotechnology company. It is also contracted to develop a bespoke OptiPhage library for an unnamed client. The company remains on track with its strategic goals. Read More

UK shareholder meetings calendar - next 7 days

1st Oct 2024 15:33

Read More

Fusion Antibodies expands agreement with National Cancer Institute

28th Aug 2024 13:52

(Alliance News) - Fusion Antibodies PLC on Wednesday said it is expanding its collaboration agreement with the National Cancer Institute. Read More

See more Fusion Antibodies news
FTSE 100 Latest
Value8,542.56
Change1.59

Login to your account

Forgot Password?

Not Registered